Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the ...

Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...

Organon will also furnish Dermavant with a $75 million milestone payment contingent upon Vtama’s approval in atopic ...

As part of the acquisition, Organon will acquire psoriasis treatment Vtama, which could soon be approved in atopic dermatitis ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...

Organon is paying $175 million upfront to buy Roivant's dermatology unit Dermavant and its topical psoriasis therapy Vtama, ...

Sen. Bernie Sanders has been probing the high prices that Novo charges for Ozempic and Wegovy. Yesterday, he share that ...

The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.

Basel, Switzerland Friday, September 20, 2024, 13:00 Hrs [IST] ...

Organon shares have stabilized in recent times, with gradual debt reduction and structural growth allowing for a valuation re ...

This funding boost will help Altamira progress their innovative pipeline while also supporting their ongoing divestment of legacy assets in allergology, viral infections, and inner ear disorders.